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Abstract
Background: Obesity-associated inflammation is of critical importance in the development of insulin resistance and non-
alcoholic fatty liver disease. Since the cannabinoid receptor CB2 regulates innate immunity, the aim of the present study
was to investigate its role in obesity-induced inflammation, insulin resistance and fatty liver.
Methodology: Murine obesity models included genetically leptin-deficient ob/ob mice and wild type (WT) mice fed a high
fat diet (HFD), that were compared to their lean counterparts. Animals were treated with pharmacological modulators of
CB2 receptors. Experiments were also performed in mice knock-out for CB2 receptors (Cnr2 2/2).
Principal Findings: In both HFD-fed WT mice and ob/ob mice, Cnr2 expression underwent a marked induction in the stromal
vascular fraction of epididymal adipose tissue that correlated with increased fat inflammation. Treatment with the CB2
agonist JWH-133 potentiated adipose tissue inflammation in HFD-fed WT mice. Moreover, cultured fat pads isolated from
ob/ob mice displayed increased Tnf and Ccl2 expression upon exposure to JWH-133. In keeping, genetic or pharmacological
inactivation of CB2 receptors decreased adipose tissue macrophage infiltration associated with obesity, and reduced
inductions of Tnf and Ccl2 expressions. In the liver of obese mice, Cnr2 mRNA was only weakly induced, and CB2 receptors
moderately contributed to liver inflammation. HFD-induced insulin resistance increased in response to JWH-133 and
reduced in Cnr2 2/2 mice. Finally, HFD-induced hepatic steatosis was enhanced in WT mice treated with JWH-133 and
blunted in Cnr2 2/2 mice.
Conclusion/Significance: These data unravel a previously unrecognized contribution of CB2 receptors to obesity-associated
inflammation, insulin resistance and non-alcoholic fatty liver disease, and suggest that CB2 receptor antagonists may open a
new therapeutic approach for the management of obesity-associated metabolic disorders.
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Introduction
Along with the alarming rise in obesity to epidemic proportions,
related complications such as diabetes mellitus, insulin resistance,
cardiovascular disease and non-alcoholic fatty liver disease
(NAFLD) are also growing and represent some of the leading
health-care concerns [1–3]. Several studies have conclusively
demonstrated that a chronic low-grade systemic inflammatory
state, predominantly arising from adipose tissue and liver, plays a
critical role in the development of these obesity-related comorbid-
ities [4–7]. Thus, in adipose tissue, fat laden adipocytes initiate the
inflammatory response by producing cytokines and chemokines,
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ment of proinflammatory macrophages and further amplification of
local inflammation [4–9]. Increased adipose tissue inflammation
will contribute to insulin resistance by disrupting insulin-dependent
signaling pathways, leading to increased delivery of free fatty acids
to the liver, and thereby contributing to hepatic steatosis [10].
Moreover, fatty liver itself also induces a local subacute inflamma-
tory state characterized by production of inflammatory mediators
such as TNFa or IL-6, that directly contribute to hepatic and
systemic insulin resistance [3].
Cannabinoid receptors CB1 and CB2 belong to the family of G
protein-coupled receptors, and bind exogenous ligands derived
from Cannabis Sativa as well as endogenous arachidonic-derived
ligands (endocannabinoids) among which anandamide or 2-
arachidonoylglycerol are the best characterized [11–13]. CB1
receptors play a key role in the pathogenesis of obesity, insulin
resistance and NAFLD via central and peripheral effects [11,14].
CB2 receptors are primarily expressed in cells of the immune
system, including macrophages, and regulate the inflammatory
response in various settings [15]. Thus, preclinical studies have
demonstrated the critical role of CB2 receptors in the inflamma-
tory process associated with rheumatoid arthritis, inflammatory
bowel diseases, atherosclerosis or liver ischemia-reperfusion injury
[15–18]. The aim of the present study was therefore to investigate
the role of CB2 receptors in obesity-associated inflammation,
insulin resistance and NAFLD.
Methods
Animals and Experimental Design
Mice used for the experiments included wild type (WT) C57Bl/
6J, ob/ob and ob+/ob male mice (Janvier, France) and mice with a
targeted mutation of the Cnr2 gene [19]. To obtain single mutant
mice on an inbred congenic genetic background, heterozygous
Cnr2 +/2 mice were backcrossed with WT C57Bl/6J (The
Jackson Laboratory) animals over 10 generations. Heterozygous
mice from the N10 generation were intercrossed to homozygous
Cnr2 2/2 animals. Genotyping was performed on tail genomic
DNA using QuantiTect
TM SYBRH Green PCR kit (Qiagen), with
the following primers: mouse Cnr2: sense 59-CTGTGCTGCTCA-
TATGCTGG-39, antisense 59-GCAGAGCGAATCTCTC-
CACT-39. We also verified that Cnr2 2/2 mice still expressed
CB1 receptors, using the following primers: mouse Cnr1: sense 59-
CTCCTGGCACCTCTTTCTCAG-39, antisense 59-GTCTCC-
TGCTGGAACCAACGG-39.
Experimental protocols were conducted in accordance with
French government policies (Services ve ´terinaires de la Sante ´e td e
la production animale, Ministe `re franc ¸ais de l9Agriculture). Adult
male mice were housed under 12 hours of light/12 hours of dark
cycle, in a temperature-controlled environment. WT C57Bl/6J
mice and Cnr2 2/2 mice (7–10 week-old) were fed a standard
chow (TD 2016, Harlan) or a high fat diet (36% fat, TD 99249,
Harlan) for 6 or 15 weeks, as indicated. Body weight and food
intake were measured weekly.
The impact of the CB2 agonist JWH-133 (Tocris, France) was
evaluated in 8-week-old C57Bl/6J mice under ND or HFD for 6
weeks that were treated with JWH-133 during the last 15 days. In
some experiments, the effect of the CB2 antagonist AM-630 (Tocris,
France) was evaluated in 6-week-old obese male mice (ob/ob)a n d
lean counterparts (ob+/ob). JWH-133 and AM-630 were freshly
dissolved in a vehicle solution containing 1 drop of Tween 20 in
0.1 ml dimethylsulfoxide (DMSO), sonicated, and further diluted 50
times in NaCl 9%. Mice received a 15-day course of daily JWH-133
(3 mg/kg) intraperitoneal injection (n=10 HFD-fed WT mice, and
n=6 ND-fed WT mice) or of 1 mg/kg AM-630 (n=10 ob/ob and
n=5ob+/ob). Control animals were treated in parallel with vehicle.
Body weight and food intake were measured daily.
In all the experiments, mice were sacrificed after overnight
fasting. White epididymal adipose tissue and liver were removed,
weighed and either fixed in buffered formalin, or snap frozen in
liquid nitrogen. All samples were stored at 280uC until use.
Preparation of adipocyte and stromal vascular fraction
(SVF) from adipose tissue
Epididymal adipose tissues from ob+/ob and ob/ob mice were
chopped and rinsed in buffer A containing 120 mM NaCl, 4 mM
KH2PO4, 1 mM MgSO4, 750 mM CaCl2, 10 mM NaHCO3 and
30 mM HEPES pH 7.4. Explants were incubated at 37uC for 30
minutes in 10 ml of buffer A supplemented with 1% BSA,
280 mM glucose and 15 mg of type 1 collagenase (Clostrido
peptidase A, Sigma). Adipocytes were then collected by filtration
and floatation, and the SVF was obtained following further
centrifugation for 15 min at 260 g and two washings in buffer A.
Purity of the fractions was evaluated by Emr1 and Adipoq
expressions (not shown). All samples were stored at 280uC until
use.
Preparation of hepatocyte and non parenchymal liver cell
fraction
Livers from ob+/ob and ob/ob mice were perfused in vivo by
LiberaseH (Roche) through portal vein. Livers were then
dissociated with forceps in Williams medium contanining 10%
FCS. Hepatocytes were obtained after filtration and sedimentation
while the supernatant was centrifugated at 300 g for 10 min to
obtain the non parenchymal cell fraction.
Adipose tissue and liver histology
Fat and liver specimens were fixed in 10% formalin, paraffin-
embedded and tissue sections (8 and 4 mm, respectively) were
stained with hematoxylin-eosin for routine examination. Adipo-
cyte size was quantified on at least 30 cells from 3 separate fields in
7 WT and 5 Cnr2 2/2 HFD-fed animals, using Image J software.
Hepatic steatosis was blindly assessed on 4 random fragments from
different areas of each liver (n=10 WT and n=10 Cnr2 2/2
HFD-fed animals), and was staged on a scale of 0 to 4, according
to the percentage of hepatocytes containing cytoplasmic vacuoles
as follows: 0, (,5%), 1 (5–20%), 2 (20%–30%), 3 (30–60%), 4
($60%).
Indirect calorimetry
In vivo indirect open circuit calorimetry was performed as
previously described [20,21]. Briefly, the mice (HFD-fed WT
(n=7) and HFD-fed Cnr22/2 (n=7)) were housed individually in
the metabolic cage at 09:30 with water, but without food.
Temperature in the metabolic cage was maintained at 32uC60.5
(low range of thermoneutrality), with an artificial 12 h–12 h light-
dark cycle. Respiratory exchanges and spontaneous activity were
continuously recorded at 10 s interval from 10:00 until 09:00 the
following day. Resting and activity-related metabolic rates were
calculated a posteriori using the Kalman filtering method [21].
Basal metabolic rate and basal RQ were defined as the mean
resting metabolic rate measured between 16:00 and 18:00 when
the mice were in a post-absorptive state, just before the 1g-test
meal was given. Post meal RQ was defined as the mean RQ
measured during 6 hrs following administration of the 1g-test meal
(until metabolic rate returned to pre-meal values); peak post meal
is defined as the highest value of RQ recorded during the post
CB2, Inflammation and Obesity
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the difference between total and resting metabolism.
Fecal fat excretion
The amount of fat in dried feces (n=7 cages of 5 mice in each
group) was measured by the Laboratory of Functional Coprology,
Pitie ´-Salpe ´trie `re Hospital, Paris France.
Culture of explants from adipose tissue
Explants of epididymal adipose tissue were prepared from ob/ob
male mice, following overnight fasting. Epididymal adipose tissue
samples were cut into small pieces (1 mm
3) under sterile conditions
and rinsed in Dulbecco’s modified Eagle medium (DMEM,
Invitrogen). Explants (200 mg) were further incubated for
48 hours at 37uC in DMEM supplemented with 12.5 mM glucose,
200 IU/ml penicillin, 50 mg/l streptomycin, and 2% BSA, and
further exposed to 1 mM JWH-133 (Tocris, France) or vehicle
(DMSO 0.02%). After 48 hours, samples were frozen in liquid
nitrogen and stored at 280uC before RNA extraction.
Serum analysis
Blood was collected at the time of sacrifice, fasting glycemia
were determined by Accu-Check active bands (Roche Diagnostics)
and insulinemia by Elisa (Ultrasensitive mouse sensitive Elisa,
Mercodia), respectively.
Hepatic triglyceride quantification
Hepatic triglycerides were extracted from 50 mg of liver
homogenates by homogenization in 1 ml of chloroform-methanol
(2:1 v/v) using TissueLyser (Qiagen). The homogenate was
centrifuged for 10 min at 1000 g, and the lipid phase was diluted
with 0.2 ml water. Following an additional centrifugation for
20 min at 2400 rpm, the lipid extract was collected from the lower
phase, evaporated and dissolved in 1 ml of 2-propanol. Triglyc-
erides were quantified with a triglyceride determination kit
(Sigma), on liver samples from 10–15 animals per group.
Insulin tolerance test
Mice (7–10 per group) underwent a 0.75 U/kg i.p. injection of
human insulin (Insulin NPH; Lilly), following a 3 h fasting. Blood
samples were taken from the tail vein for determination of
glycemia at time 0 and 20, 30, 40, 60, 90, 120, and 180 min after
the insulin injection.
Hyperinsulinemic-euglycemic clamp
Hyperinsulinemic- euglycemic clamp was performed as
previously described [22]. Briefly, 6h-fasted WT (n=6) and
Cnr2 2/2 (n=7) mice fed a HFD for 15 weeks, received
simultaneous infusions of insulin (18 mU.kg
21.min
21 for 3 h),
and D-(
3H)3-glucose (30 mCi.kg
21.min
21), Perkin Elmer, Bos-
ton, MA) to ensure a detectable D-(
3H)3-glucose enrichment.
Glycemia was assessed throughout the infusion from blood
samples collected from the tip of the tail vein and euglycemia
was maintained by adjusting a variable infusion of 30% (wt/vol)
glucose. Plasma glucose concentrations and D-(
3H)3-glucose
specific activity were determined in 5 ml of blood sampled from
the tip of the tail vein every 10 min during the last hour of the
infusion. The enrichment in D-(
3H)3-glucose was determined
from total blood after deproteinization by a Zn(OH)2 precipi-
tation as previously described [22]. An aliquot of the protein-free
supernatant was evaporated to dryness and mixed with
scintillation fluid to determine the radioactivity corresponding
to D-[
3H]3-glucose. In a second aliquot of the same supernatant,
glucose concentration was measured by the glucose oxidase
method (Sigma).
RNA preparation and RT-PCR
Total RNA was extracted from mice epididymal fat, liver and
brain using RNeasyH Lipid Tissue Mini kit (Qiagen). Quantitative
RT-PCR was carried out on a Light Cycler (Roche Diagnostics),
as previously described [23]. Oligonucleotide primer sequences of
the mouse genes studied were the following. mouse Rn18S: sense
59-ACCAGAGCGAAAGCATTTGCCA-39, antisense:5 9-
ATCGCCAGTCGGCATCGTTTAT-39; mouse Cnr2: sense
59-GGATACAGAATAGCCAGGAC-39, antisense 59-
GGAGCCGTTGGTCACTTCTG-39; mouse Cnr1: sense
59-GGGCAAATTTCCTTGTAGCA-39, antisense 59-
CTGCAAGGCCGTCTAAGATCGACT-39; mouse Ccl2: sense
59-GGGCCTGCTGTTCACAGTT-39, antisense 59-
CCAGCCTACTCATTGGGAT-39; mouse Emr1: sense
59-CTTTGGCTATGGGCTTCCAGTC-39, antisense 59-
GCAAGGAGGACAGAGTTTATCGTG-39; mouse Tnf: sense
59-AATGGCCTCCCTCTCATCAGTT-39, antisense 59-
CCACTTGGTGGTTTGCTACGA-39. PCR amplified products
were analyzed on a 2% agarose gel and sequenced.
Immunohistochemistry
Immunohistochemical detection of F4/80 was performed in
epididymal adipose formalin-fixed, parraffin-embedded tissue
sections (8 mm), using non-diluted antibody to F4/80 (Serotec
MCA 497) and biotinylated secondary antibody (1/50, Serotec
AAR10B). The signal was amplified with phosphatase alkaline–
conjugated streptavidin (1/20, Serotec), and alkaline phosphatase
activity was revealed using fast red substrate–chromogen system
(Dakocytomation). The total number of F4/80 expressing cells was
quantified on at least 500 cells from 5 random fields in 7 vehicle-
treated or 7 AM-630-treated WT mice fed a HFD, and 5 Cnr2 2/2
HFD-fed animals, using Image J software. Results are expressed as
F4/80 stained cells/total cells.
Statistics
Results are expressed as mean6SEM and were analyzed by
either Mann and Whitney test, one or two way ANOVA as
appropriate, using PRISM 4.0 software. P,0.05 was taken as the
minimum level of significance.
Results
Characterization of CB2 receptor expression in the
adipose tissue and the liver during obesity
We first characterized the expression of Cnr2 (encoding CB2) in
the adipose tissue and in the liver, and its regulation overtime
during obesity, using genetically obese leptin-deficient ob/ob mice
and wild type (WT) C57Bl/6J mice fed a high fat diet (HFD) for 6
or 15 weeks. In the two models, Cnr2 expression was detected in
the epididymal adipose tissue of lean animals, and its expression
was enhanced in obese mice in parallel to body weight increase
(Fig 1A). Moreover, in both models, the induction of fat Cnr2
expression was correlated with adipose tissue inflammation, as
shown by the concurrent increase in the expression of Emr1,
encoding the macrophage related marker F4/80 (Fig 1A). In
keeping, epididymal adipose tissue fractionation experiments
showed that Cnr2 was predominantly expressed in the stromal
vascular fraction, both in lean ob+/ob and obese ob/ob animals, and
was barely detectable in the adipocyte fraction (Fig 1B). Obesity
was associated with a modest 1.8-fold increase in Cnr2 expression
in the liver, both in ob/ob and HFD-fed animals (Fig 1C). In
CB2, Inflammation and Obesity
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expressed by the non parenchymal liver cell fraction in lean ob+/ob
and in obese ob/ob animals, whereas Cnr2 was hardly detectable in
the hepatocyte fraction (Fig 1D). Overall, these results indicate
that obesity enhances Cnr2 expression in the non parenchymal cell
fraction of adipose tissue and liver.
CB2 receptors promote obesity-associated inflammation
Given the regulatory role of Cnr2 in inflammation [15], we next
explored the possibility that CB2 receptors may regulate fat and
liver inflammation. To that aim, C57Bl/6J mice were fed a HFD
or a normal diet (ND) and sacrificed after 6 weeks, i.e at the early
onset of inflammation in obese mice. In addition, both groups of
mice received a daily intraperitoneal injection of the selective CB2
receptor agonist JWH-133 (3 mg/kg) or its vehicle during the last
2 weeks [24,25]. Administration of JWH-133 did not affect body
weight progression of either HFD or ND-fed mice (Fig 2A). As
expected, vehicle-treated HFD-fed mice showed a moderate
induction of epididymal fat Emr1 and Tnf expressions, whereas
the expression of Ccl2, encoding MCP-1, was already strongly
increased (Fig 2B). Interestingly, administration of JWH-133 to
ND-fed WT mice induced Emr1 and Tnf expression, as compared
to vehicle-treated ND counterparts (Fig 2B). Moreover, the
compound further potentiated inductions of fat Emr1 and Tnf in
HFD-fed animals (Fig 2B). However, JWH-133 treatment had no
effect on Ccl2 expression either in ND or in HFD-fed mice
(Fig 2B). The impact of JWH-133 was also investigated in
cultured fat pads isolated from ob/ob mice. Cultured fat pads
exposed to JWH-133 showed a marked induction in both Tnf and
Ccl2 expressions (Fig 2C). Finally, in the liver of mice fed a ND or
a HFD, JWH-133 had little or no effect on Ccl2 and Tnf expression
respectively (Fig 2D). Taken together, these data demonstrate that
the role of CB2 receptor is critical in adipose tissue inflammation,
but less determinant in liver inflammation.
We next investigated whether CB2 receptor antagonism
reduced obesity-associated inflammation. A 2-week treatment of
ob/ob mice with the CB2 receptor antagonist AM-630 (1 mg/kg/
day) did not affect body weight progression [26] (Fig 3A) while
reducing adipose tissue inflammation, as reflected by the reduction
in the accumulation of F4/80 positive cells and of Emr1, Tnf and
Ccl2 expression (Fig 3B and C). Moreover, in control lean ob+/ob
mice there was a trend towards reduced fat inflammation in AM-
630 treated animals compared to lean vehicle-exposed controls
(Fig 3B and C). These results were confirmed in Cnr22/2 mice
fed a HFD for 15 weeks. Compared to HFD-fed WT mice, HFD-
fed Cnr22/2 animals exhibited a significant reduction in fat
macrophage density (Fig 4A) and a lesser induction of Emr1, Tnf
and Ccl2 (Fig 4B). Finally, livers of HFD-fed Cnr22/2 mice also
showed a decline in inflammation, as compared to their WT
counterparts (Fig 4C). Overall, these data demonstrate that CB2
receptor inactivation reduces inflammation both in adipose tissue
and in the liver of obese animals.
Deletion of Cnr2 reduces body weight progression under
HFD
Surprisingly, Cnr2 knock-out was also associated with a slower
body weight progression that becomes significant after 8 weeks of
HFD (p,0.05 by two way ANOVA) (Fig 4D). Accordingly,
Cnr2 2/2 mice also displayed smaller adiposity index and
adipocyte size compared to WT animals (Table 1), and reduced
circulating leptin levels, whereas serum adiponectin levels were
unchanged (Table 1). Subsequent experiments investigated
mechanisms underlying Cnr2 impact on obesity.
Since the cannabinoid receptor CB1 plays a key role in the
pathogenesis of obesity by increasing food intake and reducing
energy expenditure, we first characterized Cnr1 expression in
brain, adipose tissue and liver. There was no difference in brain
Cnr1 expression between HFD-fed WT and Cnr22/2 mice.
However, surprisingly, Cnr1 expression was decreased in the
adipose tissue and the liver of HFD-fed Cnr2 2/2 mice as
compared to their WT counterparts (Table 1). In contrast, livers
and adipose tissue isolated from JWH-133 or AM-630 treated
animals showed no difference in Cnr1 levels (not shown). These
data suggested that the reduction of Cnr1 expression in the adipose
tissue and liver observed in Cnr2 2/2 mice might account for the
reduction in body weight progression in these animals, a reduction
that is not observed in WT mice treated with pharmacological
agonists or antagonists of CB2 receptors. The next series of
experiments were therefore designed to further delineate the
mechanisms underlying the Cnr22/2 mice phenotype.
Several studies have reported that Cnr1 knock-out decreases
food intake and increases energy expenditure. However, food
intake was similar in Cnr22/2 and WT mice fed a HFD
(Table 1). Indirect calorimetry showed that HFD-fed Cnr2 2/2
and WT mice had similar basal and total metabolic rate, exhibited
the same level of spontaneous activity (Table 1), and equivalent
thermogenic response to feeding (not shown). Nevertheless,
Cnr22/2 mice tended to display a lower pre-meal, post meal
and overall respiratory quotient, although the differences with WT
animals did not reach statistical significance (data not shown). In
addition, the peak of meal-induced RQ increase was significantly
reduced in Cnr2 2/2 animals, compared to WT (Table 1),
therefore indicating that Cnr2 knock-out may reduce the inhibition
of lipid oxidation induced by feeding. Finally, quantification of fat
elimination in faeces showed a modest albeit significant increase in
fecal lipid output in HFD-fed Cnr2 2/2 mice, as compared to
WT counterparts (Table 1), by a mechanism that may involve
inhibition of pancreatic lipase gene expression (Cadoudal et al,
preliminary results). Overall, these data indicate Cnr2 knock-out
attenuates the progression of obesity by a mechanism distinct from
that elicited by CB1 antagonism, possibly by increasing both lipid
oxidation and fecal fat excretion.
CB2 receptors promote insulin resistance
We next examined the impact of CB2 receptors on obesity-
associated insulin resistance, a reported consequence of inflam-
mation. As expected, WT mice fed a HFD for 15 weeks
developed hyperglycemia and hyperinsulinemia, resulting in
increased HOMA-IR (Fig 5A). In contrast, the increase in
insulin plasma levels and HOMA-IR was significantly lower in
HFD-fed Cnr2 2/2 mice (Fig 5A). Consistent with these results,
insulin tolerance test showed that HFD-fed Cnr2 2/2 mice were
more insulin sensitive than their WT counterparts (p,0.05 by
two way ANOVA) (Fig 5B). These findings were further
Figure 1. Selective distribution of Cnr2 in the adipose tissue and regulation during obesity. A, Time course of Cnr2 and Emr1 expression
in the epididymal adipose tissue of obese ob/ob and HFD-fed WT mice and corresponding body weight. B, Cnr2 expression was quantified in the SVF
and adipocyte fraction of ob/ob and ob+/ob mice. C, Time course of Cnr2 expression in the liver of obese ob/ob and HFD-fed WT mice. D, Cnr2
expression was quantified in the non parenchymal and parenchymal liver cell fractions of ob/ob and ob+/ob mice. *p,0.05 for ob/ob vs age-matched
ob+/ob mice or for HFD-fed vs age-matched ND-fed mice.
doi:10.1371/journal.pone.0005844.g001
CB2, Inflammation and Obesity
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(Fig 5C). Indeed, glucose turnover and glycolysis rate were
increased in HFD-fed Cnr2 2/2 mice, whereas glycogen
synthesis rate remained unchanged, confirming the insulin
sensitizing effects of Cnr2 knock-out (Fig 5C). Accordingly, in
mice exposed to a HFD for 6 weeks, treatment with the CB2
Figure 2. Activation of CB2 receptors by JWH-133 enhances fat inflammation in HFD-fed mice. WT mice were fed a HFD or a ND for 6
weeks, and treated with JWH-133 (3 mg/kg) or vehicle i.p daily during the last 15 days. A, Body weight progression during JWH-133 treatment. B,
JWH-133 increases adipose tissue inflammation. Fold induction of adipose tissue Emr1, Tnf and Ccl2 expression over control conditions (ND-fed mice
injected with vehicle). C, Activation of CB2 receptors with 1 mM JWH-133 for 48 hours up-regulates Tnf and Ccl2 expression in explants isolated from
ob/ob mice fat pads. D, Impact of JWH-133 on hepatic inflammation. Fold induction of hepatic Emr1, Tnf and Ccl2 expression over control conditions
(ND-fed mice injected with vehicle). *p,0.05 for JWH-133 vs vehicle. #p,0.05 for HFD-fed vs ND-fed mice.
doi:10.1371/journal.pone.0005844.g002
Figure 3. Pharmacological inactivation of CB2 receptors reduces the inflammatory response in the adipose tissue. ob/ob and ob+/ob
mice were daily treated for 15 days with an intraperitoneal injection of AM-630 (1 mg/kg) or vehicle. A, Body weight progression of AM-630 and
vehicle-treated ob/ob mice over time. B, C AM-630 reduces adipose tissue inflammation, as assessed by quantification of fat F4/80 stained cells/total
cells and fold induction of fat Emr1, Tnf and Ccl2 expression over control conditions (ob+/ob mice injected with vehicle). *p,0.05 for AM-630 vs
vehicle. #p,0.05 for ob/ob vs ob+/ob mice.
doi:10.1371/journal.pone.0005844.g003
CB2, Inflammation and Obesity
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insulin tolerance test (p,0.05 by two way ANOVA) ( F i g5D ) .
Collectively, these results demonstrate that CB2 receptors
enhance obesity-associated insulin resistance.
CB2 receptors promote fatty liver
Obesity-associated fatty liver has been causally linked to adipose
tissue inflammation and insulin resistance. As expected, WT mice
fed a HFD for 15 weeks developed severe fatty liver (Fig 6A).I n
contrast, HFD-fed Cnr2 2/2 animals exhibited minimal steatosis,
as illustrated by the decrease in the steatosis score (Fig 6A) and
the decline in liver triglyceride concentration, compared to HFD-
fed WT animals (Fig 6B). In keeping with these results,
administration of JWH-133 enhanced liver triglyceride accumu-
lation in WT mice fed a HFD for 6 weeks (Fig 6B). Taken
together, these findings indicate that CB2 receptors potentiate
obesity-associated fatty liver.
Discussion
Our study unravels a previously unrecognized contribution of
CB2 receptors to the pathogenesis of obesity associated-comor-
bodities via an impact on obesity-associated inflammation, insulin
resistance and fatty liver.
Recent studies have conclusively shown that adipose tissue and
liver inflammation plays a major role in obesity-associated insulin
Figure 4. Cnr2 knock-out reduces the inflammatory response in the adipose tissue and the liver. WT and Cnr2 2/2 mice were fed a HFD
or a ND for 15 weeks. A, Macrophage infiltration into epididymal fat was assessed by immunohistochemical detection of F4/80 (magnification6400)
and quantification of F4/80 stained cells/total cells. B, Fold induction of fat Emr1, Ccl2 and Tnf expression over control conditions (ND-fed WT mice).
C, Fold induction of hepatic Emr1, Ccl2 and Tnf expression over control conditions (ND-fed WT mice). D, Body weight progression over time of WT
and Cnr2 2/2 mice fed a HFD for 15 weeks (p,0.05 by two way ANOVA). *p,0.05 for HFD-fed Cnr2 2/2 vs HFD-fed WT mice. #p,0.05 in HFD-fed
WT vs ND-fed WT mice.
doi:10.1371/journal.pone.0005844.g004
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during obesity progression, Cnr2 expression undergoes a strong
increase in adipose tissue parallel to the development of fat
inflammation, and a moderate induction in the liver. Tissue
fractionation experiments show that enhancement of Cnr2
expression arises from the macrophage-enriched stromal vascular
fraction of the adipose tissue and the non parenchymal liver cell
fraction, whereas Cnr2 expression in adipocytes and hepatocytes
remains negligible. Pharmacological activation of CB2 receptors
has no significant impact on liver inflammation but promotes a
significant enhancement of adipose tissue inflammation at an
early stage. Indeed, administration of JWH-133 at the onset of
inflammation, i.e. in mice fed a HFD for 6 weeks, increases fat
macrophage infiltration and the related inflammatory response.
Moreover, pharmacological and genetic CB2 receptor inactiva-
tion reduce adipose tissue and liver inflammation in the long
term, as shown in ob/ob mice or animals fed a HFD for 15 weeks.
Interestingly, in isolated fat pads, the CB2 receptor agonist JWH-
133 upregulates Ccl2 and Tnf, demonstrating the direct impact of
CB2 receptors to adipose tissue inflammation. Nevertheless, in
light of previous data showing Cnr2 expression in human
adipocytes and in adipocyte cell lines [29,30], the contribution
of adipocyte CB2 receptors to fat inflammation cannot be
definitively ruled out. Mechanisms underlying the impact of CB2
receptors on macrophage recruitment remain to be determined.
Potential pathways could involve enhanced chemotaxis and/or
increased macrophage migration, considering reported stimula-
tory effects of CB2 receptors on these two functions in other
conditions [15,31–33]. The relative contribution of liver vs
adipose tissue inflammation remains to be determined. Never-
theless, our data unravel the critical role of CB2 receptors in
obesity-associated inflammation.
Insulin resistance associated with obesity has been linked to
adipose tissue inflammation [4–7]. In keeping with these studies,
our data suggest that proinflammatory properties of adipose tissue
CB2 receptors may contribute to the development of insulin
resistance. Indeed, under HFD, JWH-133-treated WT mice show
enhanced insulin resistance and fat inflammation, whereas
Cnr2 2/2 mice display improved insulin sensitivity and reduced
fat inflammation. It should also be stressed that, aside from their
impact on fat inflammation, CB2 receptors expressed by other
insulin sensitive tissues, including skeletal muscle and liver
[23,34,35] may also contribute to insulin resistance. In addition,
deleterious effects of CB2 receptors on insulin secretion may also
be expected, in light of the inhibition of insulin secretion triggered
by CB2 receptors expressed in pancreatic b cells [35,36].
Our results indicate that fatty liver, a hallmark of obesity-
associated metabolic syndrome, is enhanced by the CB2 receptor
agonist JWH-133 and blunted by Cnr2 knock-out. Recent data
have conclusively shown a causal relationship between obesity-
induced overproduction of fat inflammatory mediators such as
Ccl2, insulin resistance and steatogenesis. Indeed, insulin
resistance enhances the release of non-esterified fatty acids from
adipose tissue, leading to increased fatty acid storage in
hepatocytes [10]. Moreover, mice overexpressing Ccl2 specifi-
cally in adipose tissue exhibit insulin resistance and increased
hepatic triglyceride content. Conversely, knock-out of Ccl2 or its
receptor Ccr2, improves insulin sensitivity and prevents steatosis
[27,28,37]. Therefore, it is tempting to speculate that CB2
receptors may enhance fatty liver at least partly by increasing
adipose tissue inflammation and the related induction of Ccl2.
Other steatogenic mechanisms may include enhancement of
lipogenesis and/or inhibition of fatty acid b-oxidation in
hepatocytes, following direct activation of Cnr2.H o w e v e r ,
although expressed in the liver [23], CB2 receptors are
undetectable in steatotic hepatocytes.
Recentstudiesinobesepatientshavereportedelevated circulating
levels of the endogenous CB2 ligand 2-arachidonoylglycerol [38]
and increased production of the compound by fat cells [39]. These
observations, together with our findings demonstrating induction of
CB2 receptor in adipose tissue and liver, indicate that alike CB1
tone, the endogenous CB2 tone is increased during obesity [40,41].
Clinical and experimental studies in obesity have also linked
overactivation of CB1 receptors to body weight progression, insulin
resistance and fatty liver [11,14,42–45]. Interestingly, although both
receptors display convergent effects, pathways underlying CB1
effects are markedly different from those affected by CB2. Indeed,
CB1 receptors mainly enhance food intake, reduce peripheral
energy expenditure and enhance hepatic lipogenesis via CB1
receptors expressed by hepatocytes. In contrast, pharmacological
modulation of CB2 receptors has no impact on either food intake or
body weight progression and predominantly affects adipose tissue
inflammation. It should however be pointed out that Cnr2 knock-out
was associated with a slight reduction of body weight progression
under HFD, that was not observed in WT animals exposed to CB2
agonists or antagonists. This discrepancy may result from develop-
mental defects linked to lifelong absence of CB2 receptors or may be
due to the short duration of treatment with the CB2 targeting
molecules in our experiments. Nevertheless, our findings indicate
that distinct CB1 and CB2 receptor-dependent pathways signifi-
cantly contribute to the pathogenesis of insulin resistance and
NAFLD.
In conclusion, the present study uncovers the potent proin-
flammatory properties of CB2 receptors during experimental
obesity and shows the deleterious impact of CB2 receptors on
insulin resistance and fatty liver. These findings further document
Table 1. Metabolic parameters of HFD WT and Cnr2 2/2
mice.
HFD WT HFD Cnr2 2/2
Metabolism
Food intake (g/day) 2.660.00 2.760.1
Adiposity index (% of body weight) 9.660.4 6.860.8
**
Adipocyte size (mm
2) 9,9376391 6,16661,009
*
Metabolic rate (W)
Basal 0.3160.02 0.3060.00
Total 0.4460.02 0.4260.02
Spontaneous locomotor activity
(kJ/g)
0.1460.01 0.1460.00
RQ (peak post meal) 0.9260.02 0.8560.01
*
Fecal lipid (% of dry fecal weight) 19.961.5 25.963.1
*
Cnr1 expression
Brain 1.0260.01 1.4260.30
Liver 1.2160.33 0.4360.06
*
Adipose tissue 1.0460.07 0.4960.08
***
Adipokines
Leptin (mg/L) 61671 9 65
***
Adiponectin (mg/L) 11.560.6 11.260.18
*p,0.05 vs HFD WT.
**p,0.01 vs HFD WT.
***p,0.001 vs HFD WT.
doi:10.1371/journal.pone.0005844.t001
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PLoS ONE | www.plosone.org 9 June 2009 | Volume 4 | Issue 6 | e5844Figure 5. CB2 receptors potentiate insulin resistance in HFD-fed mice. A–C, Cnr2 knock-out reduces obesity-induced insulin resistance. WT
and Cnr2 2/2 mice were fed a ND or a HFD for 15 weeks A, Fasting glycemia, insulinemia, HOMA-IR; B, Blood glucose level during insulin tolerance
tests in HFD-fed mice (p,0.05 by two way ANOVA). C, Hyperinsulinemic-euglycemic clamp in HFD-fed mice, as assessed by glucose turnover rate,
whole body glycolysis and glycogen synthesis, following insulin stimulation. D, CB2 receptor activation increases insulin resistance. Blood glucose
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PLoS ONE | www.plosone.org 10 June 2009 | Volume 4 | Issue 6 | e5844the crucial role of the endocannabinoid system in metabolic
comorbidities associated to obesity, and unravel the previously
unrecognized role of CB2 receptors. They also demonstrate that
both CB1 and CB2 receptors display convergent effects, via
complementary pathways [11,13,14]. Finally, our results add
novel evidences underscoring the role of CB2 receptors in the
pathogenesis of inflammatory disorders [15] and liver diseases
[12,17,23,45–48]. Lastly, our results suggest that CB2 receptor
level during insulin tolerance tests in WT mice fed a HFD for 6 weeks and treated daily with an i.p injection of JWH-133 (3 mg/kg) or vehicle during
the last 15 days of HFD (p,0.05 by two way ANOVA). * p,0.05 for HFD-fed Cnr2 2/2 vs HFD-fed WT mice. # p,0.05 in HFD-fed WT vs ND-fed WT
mice.
doi:10.1371/journal.pone.0005844.g005
Figure 6. CB2 receptors promote the development of hepatic steatosis. A, Cnr2 knock-out blunts steatosis. Representative liver tissue
sections (magnification 6100), mean steatosis score and hepatic triglycerides in WT and Cnr2 2/2 mice fed a HFD for 15 weeks. B, Hepatic
triglycerides in HFD-fed WT or Cnr22/2 mice for 15 weeks and in vehicle or JWH-133-treated (3 mg/kg) HFD-fed WT mice for 6 weeks. *p,0.05 for
JWH-133 vs vehicle or for HFD-fed Cnr2 2/2 vs HFD-fed WT mice.
doi:10.1371/journal.pone.0005844.g006
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management of insulin resistance and fatty liver.
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